Atara Biotherapeutics Financial Statements (ATRA)
|
|
|
|
Report date
|
|
|
28.02.2022 |
08.02.2023 |
28.03.2024 |
07.03.2025 |
16.03.2026 |
|
12.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
20.3 |
63.6 |
8.57 |
128.9 |
120.8 |
|
23.1 |
|
Operating Income, bln rub |
|
|
-340.5 |
-280.5 |
-276.0 |
-83.4 |
35.9 |
|
-6.31 |
|
EBITDA, bln rub |
? |
|
-331.1 |
-222.3 |
-266.0 |
-75.7 |
38.6 |
|
-5.54 |
|
Net profit, bln rub |
? |
|
-340.1 |
-228.3 |
-276.1 |
-85.4 |
32.7 |
|
-9.47 |
|
|
OCF, bln rub |
? |
|
-220.5 |
-270.4 |
-193.0 |
-68.7 |
-50.9 |
|
-25.9 |
|
CAPEX, bln rub |
? |
|
10.6 |
4.19 |
1.22 |
0.246 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-231.1 |
-274.6 |
-194.2 |
-69.0 |
-50.9 |
|
-25.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
78.8 |
344.1 |
275.7 |
191.4 |
63.7 |
|
28.6 |
|
Cost of production, bln rub |
|
|
282.0 |
0.000 |
8.89 |
21.0 |
21.2 |
|
0.897 |
|
R&D, bln rub |
|
|
282.0 |
272.5 |
224.8 |
151.5 |
37.4 |
|
10.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.373 |
5.29 |
4.62 |
3.79 |
|
3.61 |
|
|
Assets, bln rub |
|
|
468.1 |
376.4 |
165.5 |
109.1 |
20.2 |
|
20.0 |
|
Net Assets, bln rub |
? |
|
279.6 |
126.6 |
-99.2 |
-97.3 |
-38.5 |
|
-37.3 |
|
Debt, bln rub |
|
|
28.3 |
71.7 |
57.9 |
43.8 |
52.8 |
|
9.08 |
|
Cash, bln rub |
|
|
371.1 |
242.8 |
51.7 |
42.5 |
8.48 |
|
8.36 |
|
Net debt, bln rub |
|
|
-342.8 |
-171.1 |
6.15 |
1.34 |
44.3 |
|
0.72 |
|
|
Ordinary share price, rub |
|
|
394.0 |
82.0 |
12.8 |
13.3 |
18.1 |
|
9.58 |
|
Number of ordinary shares, mln |
|
|
3.75 |
4.08 |
4.24 |
7.49 |
12.5 |
|
14.1 |
|
|
Market cap, bln rub |
|
|
1 476 |
335 |
54 |
100 |
227 |
|
135 |
|
EV, bln rub |
? |
|
1 133 |
163 |
60 |
101 |
271 |
|
136 |
|
Book value, bln rub |
|
|
280 |
127 |
-99 |
-97 |
-39 |
|
-37 |
|
|
EPS, rub |
? |
|
-90.8 |
-56.0 |
-65.2 |
-11.4 |
2.61 |
|
-0.67 |
|
FCF/share, rub |
|
|
-61.7 |
-67.3 |
-45.8 |
-9.21 |
-4.06 |
|
-1.84 |
|
BV/share, rub |
|
|
74.6 |
31.0 |
-23.4 |
-13.0 |
-3.07 |
|
-2.65 |
|
|
EBITDA margin, % |
? |
|
-1 628% |
-349.6% |
-3 103% |
-58.7% |
32.0% |
|
-23.9% |
|
Net margin, % |
? |
|
-1 672% |
-359.1% |
-3 221% |
-66.2% |
27.1% |
|
-40.9% |
|
FCF yield, % |
? |
|
-15.7% |
-82.1% |
-357.6% |
-69.2% |
-22.4% |
|
-19.2% |
|
ROE, % |
? |
|
-121.6% |
-180.3% |
278.3% |
87.8% |
-84.9% |
|
25.4% |
|
ROA, % |
? |
|
-72.7% |
-60.7% |
-166.8% |
-78.3% |
161.5% |
|
-47.3% |
|
|
P/E |
? |
|
-4.34 |
-1.47 |
-0.20 |
-1.17 |
6.94 |
|
-14.2 |
|
P/FCF |
|
|
-6.39 |
-1.22 |
-0.28 |
-1.45 |
-4.45 |
|
-5.21 |
|
P/S |
? |
|
72.6 |
5.26 |
6.34 |
0.77 |
1.88 |
|
5.83 |
|
P/BV |
? |
|
5.28 |
2.64 |
-0.55 |
-1.02 |
-5.89 |
|
-3.62 |
|
EV/EBITDA |
? |
|
-3.42 |
-0.74 |
-0.23 |
-1.33 |
7.02 |
|
-24.5 |
|
Debt/EBITDA |
|
|
1.04 |
0.77 |
-0.02 |
-0.02 |
1.15 |
|
-0.13 |
|
|
R&D/CAPEX, % |
|
|
2 665% |
6 500% |
18 380% |
61 578% |
|
|
|
|
|
CAPEX/Revenue, % |
|
|
52.0% |
6.60% |
14.3% |
0.19% |
0.00% |
|
0 |
|
| Atara Biotherapeutics shareholders |
